Has Larry Deeb received payments from drug or device companies?

Yes. Drug and device makers reported $25,632 in general payments to Larry Deeb across 169 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Larry Deeb did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Larry Deeb come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Larry Deeb

Pediatric Endocrinology · Tallahassee, FLNPI 1497741839

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,033 of the $25,632 with a category attached, or 86.0%. 42 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 49.2% of the total. Reporting peaked in 2023 at $10,552 and has fallen 91.1% since, to $935 in 2025.

$25,632in general payments, 2019–2025

Across 169 payments — averaging $151.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim International GmbH$13K
Boehringer Ingelheim Italia S.p.a.$9K
Abbott$580
Ascendis Pharma Endocrinology Inc$531
Dexcom, Inc.$335
Novo Nordisk$307
plus $2K from 36 others

$175,224in research payments, 2019–2025

Across 217 payments — averaging $807.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Ascendis Pharma Endocrinology Inc$88K
Novo Nordisk AS$55K
Boehringer Ingelheim International GmbH$25K
Eli Lilly$8K

What the payments were for

Consulting fees$22,03386%
Food & beverage$3,26113%
Education$2791%
Other$590%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim International GmbH	5	$12,600
Boehringer Ingelheim Italia S.p.a.	5	$9,433
Abbott	20	$580
Ascendis Pharma Endocrinology Inc	20	$531
Dexcom, Inc.	10	$335
Novo Nordisk	16	$307
AbbVie	13	$228
Medtronic(2 entities)	7	$222
Sanofi-aventis U.S. LLC	8	$163
Amgen	7	$113
BETA Bionics, Inc.	1	$93
Merck	6	$82
Azurity Pharmaceuticals, Inc.	4	$77
Tandem Diabetes Care, Inc.	5	$74
Valeritas, Inc.	4	$64
Pfizer	3	$59
Welch Allyn	1	$59
Johnson & Johnson	4	$54
Tolmar Pharmaceuticals, Inc.	2	$51
AstraZeneca	3	$50
Neurocrine Biosciences, Inc.	2	$40
Eton Pharmaceuticals, Inc.	1	$40
Tolmar, Inc.	2	$39
Xeris Pharmaceuticals, Inc.	2	$37
Ascensia Diabetes Care US Inc.	1	$24
Zealand Pharma US, Inc.	1	$21
Endo Pharmaceuticals Inc.	1	$20
Rhythm Pharmaceuticals, Inc.	1	$20
Soleno Therapeutics, Inc.	1	$19
Nevro Corp.	1	$18
Acella Pharmaceuticals, LLC	1	$18
Shire North American Group Inc	1	$18
Bayer	1	$18
Radius Health, Inc.	1	$16
Amarin Pharma, Inc.	1	$15
Kyowa Kirin, Inc.	1	$15
Ultragenyx Pharmaceutical Inc.	1	$14
Regeneron Healthcare Solutions, Inc.	1	$14
Corcept Therapeutics	1	$14
Tris Pharma Inc	1	$13
Lifescan, Inc.	1	$13
Ironshore Pharmaceuticals Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,632 in reported general payments places this provider in the 85th percentile of 102 pediatric endocrinology providers in Florida.

See all pediatric endocrinology providers in Florida →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	12	$1,053

Paid to pharmacies, not to this prescriber.

Other pediatric endocrinology in Tallahassee

Nancy WrightTallahassee$20K
Joshua YangOrlando$846K
Henry RodriguezTampa$211K
Dorothy ShulmanTampa$104K
Michael HallerGainesville$102K
Alejandro DiazMiami$101K
Samuel FreedmanPembroke Pines$71K
Jennifer MillerGainesville$57K
Miladys Palau CollazoPort St Lucie$54K
Laura JacobsenGainesville$36K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →